EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW

被引：0
|
作者：
Huerfano, C. [1 ]
NinoNino, C. P. [1 ]
Davila, F. [1 ]
Reyes, J. M. [2 ]
Diaz, J. A. [3 ]
机构：
[1] Univ Nacl Colombia, Bogota, Colombia
[2] Pfizer SAS, Bogota, Colombia
[3] Univ Nacl Colombia, Bogota, Colombia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1534
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN201
引用
收藏
页码：A169 / A169
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    [J]. FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [2] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [3] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [4] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
    Abd Ghafar, Nahjatul Kursyiah
    Alip, Adlinda
    Ong, Teng Aik
    Yap, Ning Yi
    Saad, Marniza
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) : 1303 - 1311
  • [6] Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
    Vuorinen, Riikka-Liisa
    Paunu, Niina
    Turpeenniemi-Hujanen, Taina
    Reunamo, Taina
    Jekunen, Antti
    Kataja, Vesa
    Sintonen, Harri
    Purmonen, Timo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    [J]. ANTICANCER RESEARCH, 2019, 39 (10) : 5559 - 5564
  • [7] Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
    J S Thompson Coon
    Z Liu
    M Hoyle
    G Rogers
    C Green
    T Moxham
    K Welch
    K Stein
    [J]. British Journal of Cancer, 2009, 101 : 238 - 243
  • [8] Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
    Coon, J. S. Thompson
    Liu, Z.
    Hoyle, M.
    Rogers, G.
    Green, C.
    Moxham, T.
    Welch, K.
    Stein, K.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 238 - 243
  • [9] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [10] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    [J]. Advances in Therapy, 2012, 29 : 202 - 217
12345